[A cooperative phase II study of vindesine sulfate in patients with solid tumors].
A cooperative phase II study of vindesine, a new vinca alkaloid, was carried out in 16 major institutions. The selection of patients and evaluation of tumor response were based on the Criteria for the Evaluation of Tumor Response by Chemotherapy in Solid Tumor Patients by Koyama and Saito. Vindesine was administered by i.v. bolus injection at a dose of 3 mg per week. Out of 130 patients who entered into the study, 117 patients were evaluable. Partial responses were obtained in 16 (13.7%) out of 117 evaluable patients, including 7 (17.1%) out of 41 lung cancer, 3 (8.1%) out of 37 breast cancer, 2 (33.3%) out of 6 esophageal cancer, and one each of cervical cancer, liposarcoma, rhabdomyosarcoma, and embryonic tumor. Major side effects were leukopenia (less than 3000/cm) 60.2%, gastrointestinal disturbances 23.6%, neurotoxicity 25.2% and hair loss 14.2%.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000188:drug therapy; D002648:Child; D004341:Drug Evaluation; D004938:Esophageal Neoplasms / Q000188:drug therapy; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008175:Lung Neoplasms / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D014747:Vinblastine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014751:Vindesine
D014747:Vinblastine; D014751:Vindesine